(Reference Translation)

Outline of Initial Listing Issue

Company Name	TAUNS Laboratories,Inc.
Scheduled Listing Date	Jun. 20, 2024
Market Section	Standard Market
Current Listed Market	N/A
Name and Title of Representative	NONAKA Masaki, President and CEO
Address of Main Office	761-1 Kamishima Izunokuni-shi Shizuoka, 410-2325 Tel. +81-558-76-8181
(Closest Point of Contact)	245-1 Doniwa Shimizu-cho Sunto-gun Shizuoka, 411-0903 Tel. +81-55-957-3090
Home Page	https://www.tauns.co.jp/en/
Date of Incorporation	Apr. 14, 2016
Description of Business	Development, manufacture and sales of in vitro diagnostics and research reagents
Category of Industry / Code	Pharmaceutical / 197A(ISIN JP3452250008)
Authorized Total No. of Shares to be Issued	400,000,000 shares
No. of Issued Shares	100,000,000 shares (As of May 17, 2024)
No. of Issued Shares (incl. treasury shares) at the Time of Listing	100,000,000 shares (Note) The number could increase as a result of the exercise of share options, etc.
Capital	JPY 200,000 thousand (As of May 17, 2024)
No. of Shares per Share Unit	100 shares
Business Year	From Jul. 1 to Jun. 30 of the following year
General Shareholders Meeting	Within 3 months after the end of the business year
Record Date	Jun. 30
Record Date of Surplus Dividend	Dec. 31 and Jun. 30
Transfer Agent	Sumitomo Mitsui Trust Bank, Limited
Auditor	ERNST & YOUNG SHINNIHON LLC
Managing Trading Participant	Daiwa Securities Co. Ltd. Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.

(Reference Translation)

<Overview of Public Offering and Secondary Distribution >

Public Offering / Secondary Distribution	Secondary Distribution (Placement Underwritten and Purchased by Principal Underwriting Participants)	21,090,000 shares
	Secondary Distribution (Placement by over-allotment scheme)	3,163,500 shares
Original Share Offerors	CITIC Capital Japan Partners III, L.P.	17,715,800 shares
	Ariake-T1 Fund LP	1,782,500 shares
	NONAKA Masaki	1,304,400 shares
	Others	287,300 shares
Offering Price Determination Method	Book-building method	
Provisional Conditions Determination Date	Jun. 4, 2024	
Book-building Period	Jun. 5, 2024 to Jun. 11, 2024	
Offering Price Determination Date	Jun. 12, 2024	
Subscription Period	Jun. 13, 2024 to Jun. 18, 2024	
Settlement Date	Jun. 20, 2024	
Principal Underwriting Participants	Daiwa Securities Co. Ltd.	
	Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.	
	Morgan Stanley MUFG Securities Co., Ltd.	
	Mizuho Securities Co., Ltd.	
	SMBC Nikko Securities Inc.	
	Nomura Securities Co.,Ltd.	
	SBI SECURITIES Co.,Ltd.	
	SHIZUGIN TM SECURITIES CO.,LTD.	
	FFG Securities Co.,Ltd.	
	AIZAWA SECURITIES CO., LTD.	
	IwaiCosmo Securities Co.,Ltd.	
	Kyokuto Securities Co., Ltd.	
	Tokai Tokyo Securities Co., Ltd.	
	TOYO SECURITIES CO.,LTD.	
	Marusan Securities Co.,Ltd.	
	MATSUI SECURITIES CO.,LTD.	
	Monex, Inc.	
	Rakuten Securities, Inc.	

(Note 1)   Tokyo Stock Exchange, Inc. approves new listings based on the results of the examination by Japan Exchange Regulation.

(Note 2)   The "Initial Listing Application Securities Report (Part I)" (only in Japanese) of the company is available on the JPX official website. Please refer to such release for details.

(Note 3)   Buy and sell market orders for this issue are prohibited in transactions carried out up to and including the initial price determination date.